Dynavax gets $30M financing deal; Dendreon inks antigen supply contract with GSK; Immatics raises $70M

> An investment fund has snapped up $2 million worth of shares in Dynavax Technologies and promised to buy up to $28 million more. The vaccine developer says the cash commitment should help it as it pursues new partnerships and other "strategic opportunities." Story

> If you've been worried about Dendreon's ability to supply its new prostate cancer vaccine Provenge, then relax. The company has signed up GlaxoSmithKline to produce the antigen used to make Provenge, with the first delivery scheduled for August 2011. Story

> Underscoring the general excitement about the market potential of therapeutic cancer vaccines, Germany's immatics has gathered more than $70 million from its Series C investors to back the development of its experimental kidney cancer vaccine. The round, one of the biggest in Europe this year, will fuel a Phase III trial designed to produce pivotal data on IMA901. Report

> BARDA awarded a $6.7 million contract to Rapid Micro BioSystems to develop a rapid sterility testing platform for vaccines. Report

> Regional efforts aimed at an AIDS vaccine must be strengthened and harmonized, says a new article in this week's PLoS Medicine Magazine. Release

> Merck is expanding its patient assistance program, offering more free drugs and vaccines. Merck release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.